Early access program for doxorubicin liposomal [ThermoDox] in patients with recurrent chest wall breast cancer

Trial Profile

Early access program for doxorubicin liposomal [ThermoDox] in patients with recurrent chest wall breast cancer

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 10 Aug 2015

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Advanced breast cancer; Liver cancer
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 10 Aug 2015 Status changed from not yet recruiting to recruiting according to a Celsion Corporation media release.
    • 10 Aug 2015 According to a Celsion Corporation media release, this EAP study was expanded to include patients with primary liver cancer and liver cancer metastases.
    • 06 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top